ATE214075T1 - Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie - Google Patents
Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapieInfo
- Publication number
- ATE214075T1 ATE214075T1 AT97926889T AT97926889T ATE214075T1 AT E214075 T1 ATE214075 T1 AT E214075T1 AT 97926889 T AT97926889 T AT 97926889T AT 97926889 T AT97926889 T AT 97926889T AT E214075 T1 ATE214075 T1 AT E214075T1
- Authority
- AT
- Austria
- Prior art keywords
- endoglin
- monoclonal antibodies
- angiogenesis
- monoclonal antibody
- endothelial cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65595396A | 1996-05-31 | 1996-05-31 | |
| PCT/US1997/009610 WO1997045450A1 (en) | 1996-05-31 | 1997-05-30 | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214075T1 true ATE214075T1 (de) | 2002-03-15 |
Family
ID=24631047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97926889T ATE214075T1 (de) | 1996-05-31 | 1997-05-30 | Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5928641A (2) |
| EP (1) | EP0938505B1 (2) |
| JP (1) | JP4318752B2 (2) |
| AT (1) | ATE214075T1 (2) |
| CA (1) | CA2256413C (2) |
| DE (1) | DE69710911T2 (2) |
| ES (1) | ES2169864T3 (2) |
| WO (1) | WO1997045450A1 (2) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| DE19845798A1 (de) * | 1998-09-29 | 2000-04-13 | Schering Ag | Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung |
| EP1150701A4 (en) * | 1999-01-22 | 2003-03-26 | Burnham Inst | TARGETING PRO-APOPTOTIC CONJUGATES AND METHODS FOR USE THEREOF |
| AU2006203034B2 (en) * | 2000-02-10 | 2006-09-07 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
| ATE406914T1 (de) * | 2000-02-10 | 2008-09-15 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
| DE10043481A1 (de) * | 2000-09-04 | 2002-04-11 | Vectron Therapeutics Ag Imt | Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung |
| JP2003021631A (ja) * | 2001-05-10 | 2003-01-24 | Chugai Pharmaceut Co Ltd | 骨転移抑制剤のスクリーニング方法 |
| WO2003028840A2 (en) * | 2001-09-27 | 2003-04-10 | Board Of Regents, The University Of Texas System | Combined compositions and methods for tumor vasculature coagulation and treatment |
| WO2005044853A2 (en) * | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
| AP2012006644A0 (en) * | 2003-08-01 | 2012-12-31 | Genentech Inc | Anti-VEGF antibodies |
| EP1533617A1 (en) * | 2003-11-19 | 2005-05-25 | RMF Dictagene S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer |
| WO2006020979A2 (en) * | 2004-08-13 | 2006-02-23 | Yale University | Factor vii conjugates for selectively treating neovascularization disorders |
| US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
| SG155257A1 (en) * | 2004-09-24 | 2009-09-30 | Beth Israel Hospital | Methods of diagnosing and treating complications of pregnancy |
| DE602005023216D1 (de) * | 2004-12-15 | 2010-10-07 | Beth Israel Hospital | Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen |
| US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| KR20170012582A (ko) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| TWI672151B (zh) | 2008-05-02 | 2019-09-21 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| EA025367B1 (ru) * | 2009-08-17 | 2016-12-30 | Тракон Фармасьютикалз, Инк. | Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| PT2510012T (pt) * | 2009-12-09 | 2017-07-13 | Bayer Pharma AG | Anticorpos anti-c4.4a e utilizações dos mesmos |
| CN103619352A (zh) | 2011-02-23 | 2014-03-05 | 健康研究公司 | 抗内皮因子抗体和表达新人/鼠嵌合内皮因子的敲入小鼠 |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN105408917B (zh) | 2013-06-14 | 2019-04-19 | 安捷伦科技有限公司 | 用于便利对象的手动分类的系统和方法 |
| GB201402006D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| AU2015346444A1 (en) | 2014-11-12 | 2017-05-04 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| RU2763916C2 (ru) | 2015-09-23 | 2022-01-11 | Дженентек, Инк. | Оптимизированные варианты анти-vegf антител |
| RU2607029C1 (ru) * | 2015-10-20 | 2017-01-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России | ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА |
| CN106928359B (zh) * | 2015-12-30 | 2020-10-13 | 广西医科大学 | 一种CD105纳米抗体Nb59 |
| CN106928355B (zh) * | 2015-12-30 | 2020-09-29 | 广西医科大学 | 一种CD105纳米抗体Nb184 |
| US11136581B2 (en) | 2016-06-24 | 2021-10-05 | University Of South Carolina | Inhibin as targetable regulators of angiogenesis |
| EP3900733A1 (en) | 2020-04-24 | 2021-10-27 | Derma Innovate S.L. | Src kinase activators and eng function inhibitors as enhancers of skin homeostasis/regeneration and hair growth |
| CN116063496B (zh) * | 2022-08-15 | 2023-10-24 | 营龄(武汉)生物科技有限公司 | 载药的人血白蛋白联合单克隆抗体在制备药物组合物中的用途 |
| CN115991773B (zh) * | 2022-08-15 | 2023-11-17 | 营龄(武汉)生物科技有限公司 | 一种含有人血白蛋白的药物组合物 |
| WO2026017807A1 (en) | 2024-07-18 | 2026-01-22 | Beech Biotech Sa | Compositions and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL94389A0 (en) * | 1989-06-01 | 1991-03-10 | Health Research Inc | Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment |
| US5776427A (en) * | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
-
1997
- 1997-05-30 ES ES97926889T patent/ES2169864T3/es not_active Expired - Lifetime
- 1997-05-30 WO PCT/US1997/009610 patent/WO1997045450A1/en not_active Ceased
- 1997-05-30 JP JP54307197A patent/JP4318752B2/ja not_active Expired - Lifetime
- 1997-05-30 CA CA002256413A patent/CA2256413C/en not_active Expired - Lifetime
- 1997-05-30 DE DE69710911T patent/DE69710911T2/de not_active Expired - Lifetime
- 1997-05-30 EP EP97926889A patent/EP0938505B1/en not_active Expired - Lifetime
- 1997-05-30 AT AT97926889T patent/ATE214075T1/de active
- 1997-08-29 US US08/920,537 patent/US5928641A/en not_active Expired - Lifetime
-
1999
- 1999-05-14 US US09/312,382 patent/US6200566B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0938505A1 (en) | 1999-09-01 |
| ES2169864T3 (es) | 2002-07-16 |
| CA2256413A1 (en) | 1997-12-04 |
| DE69710911D1 (de) | 2002-04-11 |
| US6200566B1 (en) | 2001-03-13 |
| US5928641A (en) | 1999-07-27 |
| EP0938505B1 (en) | 2002-03-06 |
| WO1997045450A1 (en) | 1997-12-04 |
| JP2000511425A (ja) | 2000-09-05 |
| JP4318752B2 (ja) | 2009-08-26 |
| DE69710911T2 (de) | 2002-09-19 |
| EP0938505A4 (en) | 2000-07-19 |
| CA2256413C (en) | 2007-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE214075T1 (de) | Monoklonale antikörper gegen endoglin und ihre verwendung in der anti-angiogenese-therapie | |
| CY1118429T1 (el) | Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου | |
| NO985150D0 (no) | Antigenbindende fragment som sµrlig sporer kreftceller, nukleoid som koder nevnte fragment, samt bruk av dette ved forebygging og pÕvisning av kreft | |
| UA111707C2 (uk) | Застосування виділеного анти-tnf-альфа антитіла людини | |
| ATE368051T1 (de) | Angiostatinfragmente und verfahren für deren verwendung | |
| ATE541860T1 (de) | Humane antikörper gegen cd40 zur therapie von b- zell tumoren | |
| EP0837696A4 (en) | IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC SUBSTANCES AT ONE DESTINATION | |
| DE3888224D1 (de) | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. | |
| EP1245676A4 (en) | HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE | |
| NO20032254L (no) | Forbindelser for inhibering av ekspresjon av VACM-I | |
| FI901551A0 (fi) | Detektering och behandling av infektioner och inflammationer. | |
| ATE168013T1 (de) | Humanisierte chimäre anti-''icam-1'' antikörper, herstellungsverfahren und verwendung | |
| DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
| DE69132048D1 (de) | Verwendung von Steroiden zur Inhibierung von Angiogenesis | |
| FI920450A0 (fi) | Metoder och kompositioner foer foerhindrande av symtomer av sepsis. | |
| CA2364026A1 (en) | Anti-tnf.alpha. antibodies in therapy of asthma | |
| DE69720996D1 (de) | Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer | |
| ATE120372T1 (de) | Antikörper für die antilymphozyten- antikörpertherapie. | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| WO1999002545A3 (en) | Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
| DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
| EA200400930A1 (ru) | Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний | |
| ATE234862T1 (de) | Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen | |
| EA200200518A1 (ru) | Способ и композиция для лечения заболеваний легких | |
| ATE97324T1 (de) | Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate. |